Cargando…
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
BACKGROUND: National payers across Europe have been increasingly looking into innovative reimbursement approaches – called managed entry agreements (MEAs) – to balance the need to provide rapid access to potentially beneficial orphan medicinal products (OMPs) with the requirements to circumscribe un...
Autores principales: | Morel, Thomas, Arickx, Francis, Befrits, Gustaf, Siviero, Paolo, van der Meijden, Caroline, Xoxi, Entela, Simoens, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882782/ https://www.ncbi.nlm.nih.gov/pubmed/24365263 http://dx.doi.org/10.1186/1750-1172-8-198 |
Ejemplares similares
-
The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
por: Xoxi, Entela, et al.
Publicado: (2021) -
Mechanism of coordinated access to orphan drugs
por: DeRidder, R, et al.
Publicado: (2012) -
A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems
por: Xoxi, Entela, et al.
Publicado: (2022) -
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
por: Facey, Karen M., et al.
Publicado: (2021) -
Managed entry agreements
por: Muscolo, Luisa AA, et al.
Publicado: (2014)